| Print
Intellia Therapeutics (NTLA)
Common SharesThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Address
40 Erie Street
Suite 130
Cambridge
MA
USA
02139
Telephone
+1 857 2856200
Forecast key dates
| Name | Key Date |
|---|---|
| Intellia Therapeutics Inc Annual General Meeting for 2027 | 2027-06-09T09:00:00 |
| Intellia Therapeutics Inc First Quarter Earnings Results for 2027 | 2027-05-11T00:00:00 |
| Intellia Therapeutics Inc Fourth Quarter Earnings Conference Call for 2026 | 2027-02-26T08:00:00 |
| Intellia Therapeutics Inc Fourth Quarter Earnings Results for 2026 | 2027-02-26T00:00:00 |
| Intellia Therapeutics Inc Annual Report for 2026 | 2027-02-26T00:00:00 |
| Intellia Therapeutics Inc Third Quarter Earnings Conference Call for 2026 | 2026-11-06T18:00:00 |
| Intellia Therapeutics Inc Third Quarter Earnings Results for 2026 | 2026-11-06T00:00:00 |
| Intellia Therapeutics Inc Second Quarter Earnings Conference Call for 2026 | 2026-08-07T08:00:00 |
| Intellia Therapeutics Inc Second Quarter Earnings Results for 2026 | 2026-08-07T00:00:00 |
| Intellia Therapeutics Inc Annual General Meeting for 2026 | 2026-06-09T09:00:00 |
| Jefferies Global Healthcare Conference | 2026-06-03T16:55:00 |
Previous key dates
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2026 AJ Bell. All rights reserved.